Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 26, 2021

SELL
$12.7 - $20.68 $698,500 - $1.14 Million
-55,000 Closed
0 $0
Q2 2021

Jul 30, 2021

BUY
$11.8 - $17.87 $166,297 - $251,841
14,093 Added 34.45%
55,000 $746,000
Q1 2021

May 03, 2021

BUY
$17.0 - $29.99 $695,419 - $1.23 Million
40,907 New
40,907 $734,000

Others Institutions Holding ADAG

About Adagene Inc.


  • Ticker ADAG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,423,200
  • Market Cap $105M
  • Description
  • Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...
More about ADAG
Track This Portfolio

Track Trellus Management Company, LLC Portfolio

Follow Trellus Management Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Trellus Management Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Trellus Management Company, LLC with notifications on news.